A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's disease who are apolipoprotein Ee4 non-carriers.
100 项与 Janssen Alzheimer Immunotherapy (Holding) Ltd. 相关的临床结果
0 项与 Janssen Alzheimer Immunotherapy (Holding) Ltd. 相关的专利(医药)
100 项与 Janssen Alzheimer Immunotherapy (Holding) Ltd. 相关的药物交易
100 项与 Janssen Alzheimer Immunotherapy (Holding) Ltd. 相关的转化医学